BioWorld

June 9, 2009

CSL, Talecris Drop Merger Plans Under FTC Pressure

Australian biotech CSL Ltd. and Talecris Biotherapeutics Inc. decided to abandon their $3.1 billion merger agreement rather than fight the Federal Trade Commission, which filed a suit to block the deal. (BioWorld Today) Read More

Micromet Gets Boost on Good Blinatumomab Data

As Several Report Trial Results at ADA, a New Obesity Target

XOMA's Phase I Diabetes Data Suggest New Path for Therapy

Aileron Closes $40M Series D as Stapled Peptides Near Clinic

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 26, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 27, 2026.

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Muted and missing M&As: JPM deals absent in 2026

BioWorld

For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...